134 related articles for article (PubMed ID: 38491984)
1. DPYD testing makes fluoropyrimidine chemotherapy safer.
Traynor K
Am J Health Syst Pharm; 2024 Apr; 81(9):e197-e198. PubMed ID: 38491984
[No Abstract] [Full Text] [Related]
2. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
3. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Brooks GA; Tapp S; Daly AT; Busam JA; Tosteson ANA
Clin Colorectal Cancer; 2022 Sep; 21(3):e189-e195. PubMed ID: 35668003
[TBL] [Abstract][Full Text] [Related]
5.
Ragia G; Biziota E; Koukaki T; Amarantidis K; Manolopoulos VG
Pharmacogenomics; 2024 Jan; 25(2):59-67. PubMed ID: 38353109
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
Lunenburg CA; van Staveren MC; Gelderblom H; Guchelaar HJ; Swen JJ
Pharmacogenomics; 2016 May; 17(7):721-9. PubMed ID: 27181275
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
[TBL] [Abstract][Full Text] [Related]
8. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Wigle TJ; Povitz BL; Medwid S; Teft WA; Legan RM; Lenehan J; Nevison S; Panuganty V; Keller D; Mailloux J; Siebring V; Sarma S; Choi YH; Welch S; Winquist E; Schwarz UI; Kim RB
Clin Transl Sci; 2021 Jul; 14(4):1338-1348. PubMed ID: 33620159
[TBL] [Abstract][Full Text] [Related]
9. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.
Medwid S; Wigle TJ; Kim RB
Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798
[TBL] [Abstract][Full Text] [Related]
10. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
11. Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.
Hertz DL; Smith DM; Scott SA; Patel JN; Hicks JK
Clin Pharmacol Ther; 2023 Oct; 114(4):768-779. PubMed ID: 37350752
[TBL] [Abstract][Full Text] [Related]
12. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
[TBL] [Abstract][Full Text] [Related]
13. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; van Werkhoven E; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Eur J Cancer; 2019 Jan; 107():60-67. PubMed ID: 30544060
[TBL] [Abstract][Full Text] [Related]
14. A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens.
Knikman JE; Lopez-Yurda M; Meulendijks D; Deenen MJ; Schellens JHM; Beijnen J; Cats A; Guchelaar HJ
Clin Pharmacol Ther; 2024 Feb; 115(2):269-277. PubMed ID: 37957132
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
16. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Saif MW
Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
[TBL] [Abstract][Full Text] [Related]
18. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
[TBL] [Abstract][Full Text] [Related]
19. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
[TBL] [Abstract][Full Text] [Related]
20. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
